Canada was forced to scrap a promising coronavirus vaccine trial after China withheld key shipments amid tensions between the two countries.
The National Research Council of Canada and CanSino Biologics had teamed up to carry out Canada's first clinical trials of a potential Covid-19 vaccine.
CanSino's vaccine, Ad5-nCov, had already showing promising results during human trials in China.
And in May Health Canada approved trials in the country to begin in Halifax.
But in July China held up shipments it was supposed to send, reports the Canadian Press.
The National Research Council said on Wednesday it had ended its partnership with CanSino.
It added that the company lacked the authority to ship the vaccine at this time.
NRC said in its statement: "Subsequent to signing, the government of China introduced process changes regarding shipping vaccines to other countries.
"The process is not clear to the NRC, but CanSino does not have the authority to ship the vaccine at this time."
China denied that the withdrawal was due to tensions between the two countries.
Paul Pogba tests positive for Covid-19 as Man Utd star is ruled out of France squad
Foreign ministry spokesman Zhao Lijian said the Chinese government supports Chinese companies working with other countries.
But Dr Xuefeng Yu, chairman and CEO of CanSino, did day the divisions within the Chinese government were unclear if the potential vaccine should "go to global trials or how to handle it".
Scott Halperin, director of the Canadian Centre for Vaccinology, said: "We were ready to start the study, had all the approvals back in June, but the company had been trying to ship us the vaccine but had not been permitted to do so.
"No matter what they tried, they were not able to get approvals to ship the vaccine.
"At this point, CanSino's already ready to go into Phase 3 studies. So this study, which was going to provide some more information, I think it's past its best-before date."
Source: Read Full Article